Publication:
Novel mutations and deletions in cystic fibrosis in a tertiary cystic fibrosis center in Istanbul

Simple item page
dc.contributor.authorKARADAĞ, BÜLENT TANER
dc.contributor.authorsAtag, Emine; Ikizoglu, Nilay Bas; Ergenekon, Almala Pinar; Gokdemir, Yasemin; Eralp, Ela Erdem; Ata, Pinar; Ersu, Refika; Karakoc, Fazilet; Karadag, Bulent
dc.date.accessioned2022-03-12T22:30:09Z
dc.date.available2022-03-12T22:30:09Z
dc.date.issued2019
dc.description.abstractBackgroundCystic fibrosis (CF) genotyping has garnered increased attention since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989 led to the identification of over 1700 mutations on chromosome 7. Yet, little is known about the genetic profile of CF patients in Turkey. This study sought to determine the mutation distribution among CF patients seeking care at Marmara University. MethodsTwo hundred fifty previously diagnosed CF patients were included in the study. CFTR gene exons 1 to 27 were amplified by a polymerase chain reaction and whole DNA sequencing was performed. Duplications and deletions were investigated by the multiplex ligation-dependent probe amplification (MLPA) technique in patients with one or two unidentified mutations in sequence analysis. ResultsCFTR mutation analysis revealed 80 mutations and five large deletions were present in our study population. The five most common mutations were (delta) F508 (c.1521-1523delCTT) (28.4%), 1677delTA (c.1545-1546delTA) (6.4%), 2789+5G->A (c.2657+5G>A) (5.8%), N1303K (c.3909C>G) (2.4%), and c.2183AA->G (c.2051-2052delAAinsG) (4.0%). Large deletions were found in 16 patients. Four novel mutations and two novel deletions were detected in this study. ConclusionsWe have identified four novel mutations and two novel deletions using next-generation DNA sequencing and the MLPA technique and obtained an overall mutation detection rate of 91.4%. Detection of novel variants in CF patients will assist in genetic counseling and in determining appropriate patients for new therapies.
dc.identifier.doi10.1002/ppul.24299
dc.identifier.eissn1099-0496
dc.identifier.issn8755-6863
dc.identifier.pubmed30938940
dc.identifier.urihttps://hdl.handle.net/11424/235449
dc.identifier.wosWOS:000474786700017
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofPEDIATRIC PULMONOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectcystic fibrosis
dc.subjectgenetics
dc.subjectpulmonology
dc.subjectCFTR GENE
dc.subjectMOLECULAR DIAGNOSIS
dc.subjectSPECTRUM
dc.subjectIDENTIFICATION
dc.subjectHAPLOTYPES
dc.subjectVARIANTS
dc.subjectTURKISH
dc.titleNovel mutations and deletions in cystic fibrosis in a tertiary cystic fibrosis center in Istanbul
dc.typearticle
dspace.entity.typePublication
local.avesis.idebaec500-4ed4-4451-ba19-777dc56cdb8e
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages8
local.journal.quartileQ2
oaire.citation.endPage750
oaire.citation.issue6
oaire.citation.startPage743
oaire.citation.titlePEDIATRIC PULMONOLOGY
oaire.citation.volume54
relation.isAuthorOfPublication218b489d-97ab-49dd-9db6-0c2a732f1999
relation.isAuthorOfPublication.latestForDiscovery218b489d-97ab-49dd-9db6-0c2a732f1999

Files

Collections

Research Outputs